Omaveloxolone, a recently FDA approved NRF2 activator, has been shown to improve neurological function in individuals with FRDA via modulation of NRF2 [81], likely by activating downstream antioxidant genes [82–85]. Here, NFE2L2 is linked to Friedreich ataxia.